NCT00381303View on ClinicalTrials.gov

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

PHASE3CompletedINTERVENTIONAL

Enrollment

429

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions

HIVInfectious

Interventions

DRUG

darunavir

600mg bid for 48 wks

DRUG

ritonavir

100mg bid for 48 wks

Trial Locations (46)

Unknown

Birmingham

Phoenix

Los Angeles

Sacramento

Torrance

Washington D.C.

Fort Lauderdale

Jacksonville

Miami

North Palm Beach

Orlando

Pensacola

Port Saint Lucie

West Palm Beach

Atlanta

Savannah

Chicago

Kansas City

New Orleans

Baltimore

Boston

Springfield

Detroit

St Louis

Neptune City

Newark

New York

The Bronx

Chapel Hill

Durham

Winston-Salem

Cincinnati

Philadelphia

Austin

Dallas

Harlingen

Houston

Longview

San Antonio

Salt Lake City

Charlottesville

Hamilton

Toronto

Montreal

Ponce

Rio Piedras

All Listed Sponsors

collaborator

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

INDUSTRY

lead

Tibotec, Inc

INDUSTRY

NCT00381303 - GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. | Biotech Hunter | Biotech Hunter